Pharmaceutical raw materials refer to various raw materials used in preparations to become finished drugs, including APIs and excipients.
APIs: APIs used in the production of various preparations are the active ingredients in the preparations. These active ingredients are prepared by chemical synthesis, plant extraction or biotechnology, usually in the form of powder, crystals, extracts, etc., but patients cannot take them directly.
Excipients: Excipients are the parts of the preparation that do not contain active ingredients. Their function is to make the active ingredients easier to absorb, stable in the body, convenient to use and process, etc. Common excipients include fillers, lubricants, dispersants, adhesives, flavoring agents, etc.
Active Pharmaceutical Ingredients (APIs), excipients, solvents, intermediates, etc.
| Quality and Compliance | Certifications like GMP, ISO, and FDA standards. |
Purity and impurity control | The purity of raw materials must meet the requirements of the pharmacopoeia, and the impurity content should be within an acceptable range to ensure the quality and efficacy of the final drug. |
Cost vs. Value | The price of raw materials provided by suppliers should be competitive in the market, taking quality factors into consideration |
Technical support and after-sales service | Suppliers should be able to provide necessary technical support, including raw material usage recommendations, problem solving, etc. Good after-sales service can ensure that problems are solved in a timely manner and reduce production risks. |
Supply chain security and sustainability | Consider whether the supplier’s supply chain is stable and whether there are potential risk points. Suppliers should pay attention to environmental protection and sustainable development to ensure that the collection and production process of raw materials have little impact on the environment. |
Asia-Pacific (China, India) | Abundant raw material resources, low production costs, growing market demand, strong production capacity and active government support. |
| Europe | High standards, quality, and regulatory framework. |
| North America | Focus on innovation and high-quality raw materials. |
Tianming Pharmaceutical Group has a number of high-standard professional laboratories, covering fields such as synthesis, fermentation, polymer and formulation R&D. Its R&D area exceeds 6,000 square meters, and it has a high-tech R&D team of more than 100 people. This enables Tianming to have comprehensive strength from laboratory research, pilot scale-up to industrial production. Tianming has authoritative advantages in the development of production processes for pharmaceutical raw materials and intermediates, and has more than ten pharmaceutical industry-related patents, such as “A Preparation Method of Trelagliptin” and “A Preparation Method of Cefmenoxime Hydrochloride”.
Tianming’s product line is extensive, covering multiple fields such as cardiovascular drugs, diabetes drugs, anti-tumor drugs and antiviral products. Its raw materials and intermediates include LCZ696, alogliptin, linagliptin, empagliflozin, finerenone, ibrutinib, baricitinib, tofacitinib, baloxavir, etc. These products are strictly quality controlled to ensure compliance with domestic and international pharmacopoeia standards.
Tianming pays attention to product quality and has established a complete quality control system. The company has ISO quality management system certification and production site “6S” management certification to ensure that every link from raw material procurement to product production meets high standards of quality requirements. This makes Tianming’s products have extremely high credibility and competitiveness in the market.
Tianming is committed to providing customers with high-quality customer service and technical support. The company has a professional sales team and technical team that can provide customers with timely and professional consultation and solutions. At the same time, Tianming also pays attention to long-term cooperation with customers, and meets the changing needs of customers through continuous technological innovation and optimized services.
Tianming Pharmaceutical Group has won many honorary titles, such as “Provincial Specialization and New”, “Dezhou Anti-diabetic Drug Key Laboratory”, “Science and Technology-based Small and Medium-sized Enterprises” and “One Enterprise, One Technology”. The acquisition of these honors is not only a recognition of Tianming’s strength in the field of pharmaceutical raw materials, but also an affirmation of its good corporate reputation and social responsibility.
As a company specializing in the production of APIs and intermediates, Tianming Pharmaceutical has rich experience and a professional team, and can provide you with a full range of support and services. If you have any needs for purchasing APIs, please contact our team immediately, and we will serve you wholeheartedly.
As a leading API/intermediate manufacturer, we showcase advanced synthesis tech and regulatory-ready solutions at CPHI 2025. Booth No.: W2G30
Expert analysis of API synthesis complexities: route selection trade-offs, scale-up challenges, impurity control tactics, and green chemistry innovations. Includes industrial case studies on yield optimization and troubleshooting.
This guide reveals why your Pharmaceutical Ingredient List is vital for compliance and innovation. Learn sourcing strategies, quality benchmarks, and 2024 API trend（Attached API list）
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.